Clinical Report: New dopamine agonist enters Parkinson disease care
Overview
The FDA has approved tavapadon (Juvmo) for adults with Parkinson disease, supported by the phase 3 TEMPO clinical trial program. The trial evaluated tavapadon in patients with early Parkinson disease and as an adjunct to oral levodopa in patients with motor fluctuations.
Background
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions globally, leading to significant morbidity. The management of PD primarily focuses on alleviating motor symptoms through dopaminergic treatments, including levodopa and dopamine agonists.
Data Highlights
Trial
Outcome
Tavapadon (5 mg)
Tavapadon (15 mg)
Placebo
TEMPO-1
Part II MDS-UPDRS Score Change
-1.6
-1.7
+0.9
TEMPO-1
Combined Part II & III Score Change
-9.7
-10.2
+1.8
TEMPO-2
Part II Score Change
-1.5
-
0
TEMPO-2
Combined Part II & III Score Change
-10.3
-
-1.2
TEMPO-3
Daily “on” time without troublesome dyskinesia
+1.7 hours
-
+0.6 hours
Key Findings
Tavapadon improved activities of daily living at week 26 in TEMPO-1 compared to placebo.
In TEMPO-1, combined Part II and III scores decreased by 9.7 and 10.2 points for the 5 mg and 15 mg doses, respectively.
TEMPO-2 showed a decrease of 1.5 points in Part II scores with tavapadon compared to no change with placebo.
TEMPO-3 demonstrated an increase of 1.7 hours in daily “on” time without troublesome dyskinesia with tavapadon plus oral levodopa.
Most treatment-emergent adverse events were mild or moderate, including nausea, headache, and dizziness.
AbbVie anticipates tavapadon will be available in the US by October 2026.
Clinical Implications
Clinicians should be aware of the potential adverse effects associated with tavapadon, particularly in patients receiving it alongside oral levodopa.
Conclusion
Tavapadon has been approved for the treatment of Parkinson disease, with evidence from clinical trials regarding its effects on motor symptoms and daily functioning.
